HALO logo

Halozyme Therapeutics (HALO) CAPEX

Annual CAPEX

$10.70 M
-$4.60 M-30.06%

December 31, 2024

Summary

Performance

1-Year Change

-30.06%

3-Year Change

+634.11%

5-Year Change

+164.75%

15-Year Change

+692.3%

HALO CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

66.59%
HALO annual capital expenditures is higher than 66.59% of companies in Healthcare sector

High & Low

All-time High

$15.29 M
HALO annual capital expenditures is currently -30.06% below its historical high of $15.29 million

3-Year Low

$1.46 M
HALO annual capital expenditures is currently +634.11% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
HALO previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
HALO next annual earnings announcement has not yet been scheduled

OtherHALOcash flowmetrics:

Annual FCF

$468.37 M
HALO annual free cash flow is $468.37 million

Annual CFO

$479.06 M
HALO annual cash flow from operations is $479.06 million

Annual CFI

-$262.72 M
HALO annual cash flow from investing activities is -$262.72 million

Annual CFF

-$218.86 M
HALO annual cash flow from financing activities is -$218.86 million

Quarterly CAPEX

$3.05 M
+$1.53 M+101.19%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+17.57%

3-Year Change

+3.67%

5-Year Change

+3.67%

HALO Quarterly CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

68.96%
HALO quarterly capital expenditures is higher than 68.96% of companies in Healthcare sector

High & Low

All-time High

$11.38 M
HALO quarterly capital expenditures is currently -73.17% below its historical high of $11.38 million

3-Year Low

-$1.62 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
HALO previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 7, 2025
HALO next earnings announcement is scheduled for May 7, 2025

OtherHALOcash flowmetrics:

Quarterly FCF

$175.41 M
HALO quarterly free cash flow is $175.41 million

Quarterly CFO

$178.47 M
HALO quarterly cash flow from operations is $178.47 million

Quarterly CFI

$29.48 M
HALO quarterly cash flow from investing activities is $29.48 million

Quarterly CFF

-$246.41 M
HALO quarterly cash flow from financing activities is -$246.41 million

TTM CAPEX

$10.70 M
+$456.00 K+4.45%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

-30.06%

3-Year Change

-28.89%

5-Year Change

-28.89%

HALO TTM CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

66.62%
HALO TTM capital expenditures is higher than 66.62% of companies in Healthcare sector

High & Low

All-time High

$15.70 M
HALO TTM capital expenditures is currently -31.86% below its historical high of $15.70 million

3-Year Low

$1.46 M
HALO TTM capital expenditures is currently +634.11% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
HALO previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 7, 2025
HALO next earnings announcement is scheduled for May 7, 2025

OtherHALOcash flowmetrics:

TTM FCF

$468.37 M
HALO TTM free cash flow is $468.37 million

TTM CFO

$479.06 M
HALO TTM cash flow from operations is $479.06 million

TTM CFI

-$262.72 M
HALO TTM cash flow from investing activities is -$262.72 million

TTM CFF

-$218.86 M
HALO TTM cash flow from financing activities is -$218.86 million

HALO CAPEX Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-30.1%+17.6%-30.1%
3 y3 years+634.1%+3.7%-28.9%
5 y5 years+164.8%+3.7%-28.9%

HALO CAPEX Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-30.1%+634.1%-73.2%+288.1%-31.9%+634.1%
5 y5-year-30.1%+634.1%-73.2%+288.1%-31.9%+639.7%
alltimeall time-30.1%+4591.2%-73.2%+139.0%-31.9%+236.6%

Halozyme Therapeutics CAPEX History

DateAnnualQuarterlyTTM
Dec 2024
$10.70 M(-30.1%)
$3.05 M(+101.2%)
$10.70 M(+4.5%)
Sep 2024
-
$1.52 M(-41.2%)
$10.24 M(-12.2%)
Jun 2024
-
$2.58 M(-27.2%)
$11.67 M(+56.4%)
Mar 2024
-
$3.54 M(+36.6%)
$7.46 M(-51.2%)
Dec 2023
$15.29 M(+218.0%)
$2.60 M(-11.8%)
$15.29 M(+1.7%)
Sep 2023
-
$2.94 M(-281.4%)
$15.04 M(+14.8%)
Jun 2023
-
-$1.62 M(-114.3%)
$13.11 M(-16.5%)
Mar 2023
-
$11.38 M(+385.4%)
$15.70 M(+226.3%)
Dec 2022
$4.81 M(+230.1%)
$2.34 M(+132.5%)
$4.81 M(+83.3%)
Sep 2022
-
$1.01 M(+4.1%)
$2.62 M(+24.2%)
Jun 2022
-
$968.00 K(+97.6%)
$2.11 M(+25.9%)
Mar 2022
-
$490.00 K(+210.1%)
$1.68 M(+15.1%)
Dec 2021
$1.46 M(-41.8%)
$158.00 K(-68.1%)
$1.46 M(-51.4%)
Sep 2021
-
$496.00 K(-6.9%)
$3.00 M(+11.9%)
Jun 2021
-
$533.00 K(+97.4%)
$2.68 M(+0.7%)
Mar 2021
-
$270.00 K(-84.1%)
$2.66 M(+6.2%)
Dec 2020
$2.50 M(-38.0%)
$1.70 M(+865.3%)
$2.50 M(+73.2%)
Sep 2020
-
$176.00 K(-65.8%)
$1.45 M(-39.1%)
Jun 2020
-
$515.00 K(+351.8%)
$2.37 M(-26.4%)
Mar 2020
-
$114.00 K(-82.2%)
$3.23 M(-20.1%)
Dec 2019
$4.04 M(-13.4%)
$641.00 K(-41.9%)
$4.04 M(-37.6%)
Sep 2019
-
$1.10 M(-19.3%)
$6.47 M(+13.5%)
Jun 2019
-
$1.37 M(+47.6%)
$5.70 M(+20.0%)
Mar 2019
-
$927.00 K(-69.8%)
$4.75 M(+1.9%)
Dec 2018
$4.66 M(+245.4%)
$3.07 M(+822.8%)
$4.66 M(+90.3%)
Sep 2018
-
$333.00 K(-20.3%)
$2.45 M(+7.6%)
Jun 2018
-
$418.00 K(-50.2%)
$2.28 M(+9.0%)
Mar 2018
-
$839.00 K(-2.4%)
$2.09 M(+54.8%)
Dec 2017
$1.35 M(-57.0%)
$860.00 K(+434.2%)
$1.35 M(+44.1%)
Sep 2017
-
$161.00 K(-30.0%)
$937.00 K(-21.9%)
Jun 2017
-
$230.00 K(+132.3%)
$1.20 M(-43.8%)
Mar 2017
-
$99.00 K(-77.9%)
$2.14 M(-31.9%)
Dec 2016
$3.14 M(+32.9%)
$447.00 K(+5.4%)
$3.14 M(-27.5%)
Sep 2016
-
$424.00 K(-63.7%)
$4.32 M(+2.1%)
Jun 2016
-
$1.17 M(+6.2%)
$4.24 M(+27.2%)
Mar 2016
-
$1.10 M(-32.7%)
$3.33 M(+41.1%)
Dec 2015
$2.36 M(+72.5%)
$1.63 M(+386.3%)
$2.36 M(+145.3%)
Sep 2015
-
$336.00 K(+29.2%)
$962.00 K(-3.5%)
Jun 2015
-
$260.00 K(+100.0%)
$997.00 K(-8.3%)
Mar 2015
-
$130.00 K(-44.9%)
$1.09 M(-20.5%)
Dec 2014
$1.37 M
$236.00 K(-36.4%)
$1.37 M(-45.1%)
Sep 2014
-
$371.00 K(+6.0%)
$2.49 M(+1.9%)
Jun 2014
-
$350.00 K(-14.8%)
$2.44 M(+12.4%)
DateAnnualQuarterlyTTM
Mar 2014
-
$411.00 K(-69.7%)
$2.17 M(-5.4%)
Dec 2013
$2.30 M(+62.6%)
$1.36 M(+317.8%)
$2.30 M(+55.3%)
Sep 2013
-
$325.00 K(+306.3%)
$1.48 M(+11.9%)
Jun 2013
-
$80.00 K(-85.0%)
$1.32 M(-32.1%)
Mar 2013
-
$534.00 K(-1.1%)
$1.95 M(+37.8%)
Dec 2012
$1.41 M(+70.5%)
$539.80 K(+222.3%)
$1.41 M(-1.2%)
Sep 2012
-
$167.50 K(-76.3%)
$1.43 M(+9.9%)
Jun 2012
-
$705.60 K(+26.7%)
$1.30 M(+57.1%)
Dec 2011
$828.50 K(+28.2%)
$557.00 K(+1328.2%)
$828.50 K(+37.6%)
Sep 2011
-
$39.00 K(+32.2%)
$602.20 K(-3.5%)
Jun 2011
-
$29.50 K(-85.5%)
$623.80 K(-10.9%)
Mar 2011
-
$203.00 K(-38.6%)
$700.40 K(+8.4%)
Dec 2010
$646.50 K(-55.7%)
$330.70 K(+445.7%)
$646.40 K(-26.5%)
Sep 2010
-
$60.60 K(-42.9%)
$879.10 K(-9.3%)
Jun 2010
-
$106.10 K(-28.8%)
$969.40 K(-24.9%)
Mar 2010
-
$149.00 K(-73.6%)
$1.29 M(-11.6%)
Dec 2009
$1.46 M(+26.0%)
$563.40 K(+273.4%)
$1.46 M(+27.0%)
Sep 2009
-
$150.90 K(-64.7%)
$1.15 M(-19.8%)
Jun 2009
-
$427.80 K(+34.1%)
$1.43 M(+12.6%)
Mar 2009
-
$319.00 K(+26.4%)
$1.27 M(+9.8%)
Dec 2008
$1.16 M(-51.0%)
$252.40 K(-42.0%)
$1.16 M(-40.2%)
Sep 2008
-
$435.40 K(+63.1%)
$1.94 M(-0.1%)
Jun 2008
-
$267.00 K(+30.2%)
$1.94 M(-19.4%)
Mar 2008
-
$205.00 K(-80.2%)
$2.41 M(+1.9%)
Dec 2007
$2.37 M(+548.4%)
$1.03 M(+136.6%)
$2.37 M(+64.1%)
Sep 2007
-
$436.70 K(-40.5%)
$1.44 M(+24.2%)
Jun 2007
-
$734.50 K(+356.5%)
$1.16 M(+138.5%)
Mar 2007
-
$160.90 K(+47.2%)
$486.80 K(+33.4%)
Dec 2006
$364.80 K(+4.0%)
$109.30 K(-30.0%)
$364.80 K(+38.8%)
Sep 2006
-
$156.20 K(+158.6%)
$262.90 K(+29.3%)
Jun 2006
-
$60.40 K(+55.3%)
$203.40 K(-21.5%)
Mar 2006
-
$38.90 K(+425.7%)
$259.10 K(-26.2%)
Dec 2005
$350.90 K(+53.9%)
$7400.00(-92.3%)
$350.90 K(-23.6%)
Sep 2005
-
$96.70 K(-16.7%)
$459.00 K(+18.9%)
Jun 2005
-
$116.10 K(-11.2%)
$386.20 K(+22.0%)
Mar 2005
-
$130.70 K(+13.2%)
$316.60 K(+38.9%)
Dec 2004
$228.00 K
$115.50 K(+383.3%)
$227.90 K(+328.4%)
Sep 2004
-
$23.90 K(-48.6%)
$53.20 K(+21.2%)
Jun 2004
-
$46.50 K(+10.7%)
$43.90 K(-100.6%)
Mar 2004
-
$42.00 K(-170.9%)
-$7.83 M(>+9900.0%)
Dec 2003
-
-$59.20 K(-505.5%)
-$100.00(-100.2%)
Sep 2003
-
$14.60 K(-100.2%)
$59.10 K(+32.8%)
Jun 2003
-
-$7.83 M(-199.4%)
$44.50 K(-99.4%)
Mar 2003
-
$7.87 M
$7.87 M

FAQ

  • What is Halozyme Therapeutics annual capital expenditures?
  • What is the all time high annual CAPEX for Halozyme Therapeutics?
  • What is Halozyme Therapeutics annual CAPEX year-on-year change?
  • What is Halozyme Therapeutics quarterly capital expenditures?
  • What is the all time high quarterly CAPEX for Halozyme Therapeutics?
  • What is Halozyme Therapeutics quarterly CAPEX year-on-year change?
  • What is Halozyme Therapeutics TTM capital expenditures?
  • What is the all time high TTM CAPEX for Halozyme Therapeutics?
  • What is Halozyme Therapeutics TTM CAPEX year-on-year change?

What is Halozyme Therapeutics annual capital expenditures?

The current annual CAPEX of HALO is $10.70 M

What is the all time high annual CAPEX for Halozyme Therapeutics?

Halozyme Therapeutics all-time high annual capital expenditures is $15.29 M

What is Halozyme Therapeutics annual CAPEX year-on-year change?

Over the past year, HALO annual capital expenditures has changed by -$4.60 M (-30.06%)

What is Halozyme Therapeutics quarterly capital expenditures?

The current quarterly CAPEX of HALO is $3.05 M

What is the all time high quarterly CAPEX for Halozyme Therapeutics?

Halozyme Therapeutics all-time high quarterly capital expenditures is $11.38 M

What is Halozyme Therapeutics quarterly CAPEX year-on-year change?

Over the past year, HALO quarterly capital expenditures has changed by +$456.00 K (+17.57%)

What is Halozyme Therapeutics TTM capital expenditures?

The current TTM CAPEX of HALO is $10.70 M

What is the all time high TTM CAPEX for Halozyme Therapeutics?

Halozyme Therapeutics all-time high TTM capital expenditures is $15.70 M

What is Halozyme Therapeutics TTM CAPEX year-on-year change?

Over the past year, HALO TTM capital expenditures has changed by -$4.60 M (-30.06%)